KR20150016666A - A process for preparing bowel cleansing composition containing pico sodium sulfate and the composition - Google Patents
A process for preparing bowel cleansing composition containing pico sodium sulfate and the composition Download PDFInfo
- Publication number
- KR20150016666A KR20150016666A KR1020130092376A KR20130092376A KR20150016666A KR 20150016666 A KR20150016666 A KR 20150016666A KR 1020130092376 A KR1020130092376 A KR 1020130092376A KR 20130092376 A KR20130092376 A KR 20130092376A KR 20150016666 A KR20150016666 A KR 20150016666A
- Authority
- KR
- South Korea
- Prior art keywords
- sodium
- composition
- parts
- prepare
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 title claims abstract description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 title claims abstract description 14
- 235000011152 sodium sulphate Nutrition 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 21
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 21
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000008187 granular material Substances 0.000 claims abstract description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 15
- 239000011734 sodium Substances 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 44
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 22
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 claims description 18
- 229960005077 sodium picosulfate Drugs 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920005596 polymer binder Polymers 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000002998 adhesive polymer Substances 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000004376 Sucralose Substances 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000005708 Sodium hypochlorite Substances 0.000 claims 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims 4
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 26
- 238000005406 washing Methods 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- UJIDKYTZIQTXPM-UHFFFAOYSA-N [4-[pyridin-2-yl-(4-sulfooxyphenyl)methyl]phenyl] hydrogen sulfate Chemical compound C1=CC(OS(=O)(=O)O)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 UJIDKYTZIQTXPM-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 235000019614 sour taste Nutrition 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002491 polymer binding agent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940085912 calcium carbonate 200 mg Drugs 0.000 description 1
- 229940085862 calcium carbonate 500 mg Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 229940005592 picosulfurate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- -1 that is Substances 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 피코황산나트륨 함유 장 세척용 조성물의 제조방법 및 그 조성물에 관한 것으로, 좀 더 상세하게 설명하자면 피코황산나트륨과 산화마그네슘 및 구연산을 활성성분으로 포함하되, 먼저 상기 피코황산나트륨을 탄산칼슘의 표면에 부착하여 과립물을 제조하고, 이어 상기 과립물과 산화마그네슘 및 구연산을 차례로 혼합하여서 제조되는 것을 특징으로 하는 장 세척용 조성물의 제조방법과, 이러한 방법으로 제조되는 장 세척용 조성물에 관한 것이다.
본 발명에 따른 장 세척용 조성물은, 품질이 균일하고, 복약 순응도가 우수한 장점이 있다. The present invention relates to a method for preparing a composition for the treatment of intestinal pico sodium sulphate, and more particularly, to a method for preparing a composition for intestinal pico sulphate containing sodium pico sodium sulfate, And then mixing the granules with magnesium oxide and citric acid in order to prepare a composition for intestinal washing, and a composition for intestinal washing prepared by such a method.
The composition for intestinal washing according to the present invention is advantageous in that the quality is uniform and the compliance with medication is excellent.
Description
본 발명은 피코황산나트륨 함유 장 세척용 조성물의 제조방법 및 그 조성물에 관한 것으로, 좀 더 상세하게 설명하자면 피코황산나트륨과 산화마그네슘 및 구연산을 활성성분으로 포함하되, 먼저 상기 피코황산나트륨을 탄산칼슘의 표면에 부착하여 과립물을 제조하고, 상기 과립물과 산화마그네슘 및 구연산을 차례로 혼합하여서 제조되는 것을 특징으로 하는 장 세척용 조성물의 제조방법과, 이러한 방법으로 제조되는 장 세척용 조성물에 관한 것이다.
The present invention relates to a method for preparing a composition for the treatment of intestinal pico sodium sulphate, and more particularly, to a method for preparing a composition for intestinal pico sulphate containing sodium pico sodium sulfate, To prepare granules, and then mixing the granules with magnesium oxide and citric acid in order. The present invention also relates to a method for preparing a bowel cleansing composition and a bowel cleansing composition prepared by such a method.
일반적으로 X 선 검사나, 대장 내시경, 방사선 촬영 또는 장 수술 전에는 사전에 장 내부를 완전히 비우는 조치를 취하게 되는데, 이러한 목적으로 복용하는 약물이 장 세척제이다. 종래에는 주로 폴리에칠렌 글리콜과 전해질 용액을 장 세척제로 사용하고 있으나, 이러한 약물은 단시간 내에 약 4리터 정도의 액체를 계속 복용해야 하기 때문에 대부분의 환자들이 구역질이나 구토, 경련 등과 같은 부작용을 경험하게 되고, 이로 인해 복약 순응도가 매우 저조한 문제가 있다.Generally, before X-ray examination, colonoscopy, radiography or intestinal surgery, the patient takes measures to completely empty the intestines beforehand. For this purpose, the drug to be used is the intestinal cleanser. Conventionally, polyethylene glycol and electrolytic solution are mainly used as long-term cleansers. However, most of the patients experience side effects such as nausea, vomiting, and seizures because they have to continuously take about 4 liters of liquid in a short time, There is a problem that compliance with medication is very low.
그래서 최근에는 피코황산나트륨과 산화마그네슘 및 구연산을 활성성분으로 하는 분말 또는 과립 형태의 장 세척제(상품명; PICOLAX )가 개발, 시판되고 있다. 여기서 상기 피코황산나트륨은 자극성 하제이고, 상기 산화마그네슘과 구연산은 삼투성 완하제인 구연산 마그네슘을 형성한다. 이러한 장 세척제는 종래의 폴리에칠렌 글리콜 제제에 비해 복용량을 약 10분의 1 미만으로 대폭 감소시킬 수 있는 장점이 있으나, 피코황산나트륨의 유효 함량(10mg)이 전체 조성물의 0.06 중량% 정도에 불과하기 때문에 제조 과정에서 제품의 균질성을 확보하기가 매우 어려운 문제가 있다.Recently, powdery or granular long-term detergent (trade name: PICOLAX) containing sodium picosalphate, magnesium oxide and citric acid as an active ingredient has been developed and marketed. Wherein the sodium picosulfate is a stimulant, and the magnesium oxide and citric acid form an osmotic laxative magnesium citrate. Such a long-term cleanser has the advantage of drastically reducing the dosage to less than about one-tenth of that of conventional polyethylene glycol preparations. However, since the effective content (10 mg) of sodium picosulfate is only about 0.06% by weight of the total composition, There is a problem that it is very difficult to ensure homogeneity of the product in the process.
이러한 과제를 해결하기 위하여 국내 특허공개 제10-2010-0072020호(2010년 06월 29일에는, 피코황산나트륨 용액을 중탄산칼륨에 분무하는 단계와 상기 피코황산나트륨 및 중탄산칼륨을 건조하는 단계를 포함하고, 피코황산나트륨, 구연산, 산화마그네슘, 중탄산칼륨 및 선택적으로 사카린 나트륨 및/또는 오렌지 향료를 포함하여 이루어진 약제학적 조성물의 제조방법이 소개되어 있다.In order to solve this problem, Korean Patent Laid-Open No. 10-2010-0072020 (Jun. 29, 2010) includes a step of spraying a sodium picosulfate solution onto potassium bicarbonate and a step of drying the sodium picosulfate and potassium bicarbonate, A process for the preparation of pharmaceutical compositions comprising sodium picosalpate, citric acid, magnesium oxide, potassium bicarbonate and optionally sodium saccharin and / or orange flavor has been introduced.
또한, 국내 특허 제10-1155099호(2012년 06월 04일)에는, 피코황산나트륨과 산화마그네슘을 혼합하여 제1 예비 혼합물을 형성하고, 상기 제1 예비 혼합물에 산화마그네슘을 추가로 첨가하여 혼합하는 배산 공정을 복수 회 수행하여 제1 혼합물을 형성하며, 탄산수소나트륨을 포함하는 제2 혼합물을 형성하고, 상기 제1 혼합물, 제2 혼합물 및 구연산을 혼합하여 제3 혼합물을 형성하는 것을 포함하는 장 세척용 조성물의 제조방법이 소개되어 있다.In addition, in Korean Patent No. 10-1155099 (Jun. 04, 2012), pico sodium sulfate and magnesium oxide are mixed to form a first preliminary mixture, and magnesium oxide is further added to the first preliminary mixture to be mixed A step of performing the dewaxing process a plurality of times to form a first mixture, forming a second mixture comprising sodium bicarbonate, and mixing the first mixture, the second mixture and citric acid to form a third mixture A method of making a cleaning composition is introduced.
그러나 이러한 종래의 방법으로 제조된 장세척용 조성물들은 제조과정에서 유연물질이 발생하게 될 우려가 있고, 제제학적으로 정제로의 제조가 용이하지 않을 뿐 아니라, 환자가 상기 조성물을 복용하기 위해 물에 용해하였을 때 약간의 비릿한 입맛을 느끼게 한다는 점에서 여전히 개선의 여지가 남아 있었다.
However, the composition for intestinal cleansing produced by such a conventional method is liable to generate a soft substance in the manufacturing process, and it is not easy to prepare tablets by pharmaceutical preparation, There was still room for improvement in that it made the user feel a slight bitter taste when melted.
본 발명이 해결하고자 하는 과제는 미량의 피코황산나트륨을 비롯한 각 구성성분들이 골고루 분포되어 있어서 품질이 균일하고, 유연물질이 발생하지 않으며, 정제 제조가 용이하고, 물에 용해하였을 때 비린 맛을 최소화하여 복약 순응도를 향상시킬 수 있는 피코황산나트륨 함유 장 세척용 조성물의 제조방법과, 이러한 방법으로 제조된 장 세척용 조성물을 제공하는 것이다.
The problem to be solved by the present invention is to provide a process for producing a picolinate having a uniform quality of each ingredient including a trace amount of sodium picosapenta sulfate and having no occurrence of a soft substance and easy preparation of a tablet, A method for preparing a composition for intestinal pico sulphate-containing detergent capable of improving compliance with medicines, and a composition for intestinal washing prepared by such a method.
본 발명에 따른 피코황산나트륨 함유 장 세척용 조성물의 제조방법은, 피코황산나트륨을 결합용매에 투입하고, 여기에 점착성 고분자 결합제를 용해하여 결합액을 제조하는 단계와; 상기 결합액을 탄산칼슘의 표면에 부착하고, 상기 결합용매를 제거하여 1차 과립물을 제조하는 단계와; 상기 1차 과립물에다 산화마그네슘을 혼합하여 1차 혼합물을 제조하는 단계와; 상기 1차 혼합물에다 구연산을 혼합하여 2차 혼합물을 제조하는 단계; 를 포함하는 것을 특징으로 한다.A method for preparing a composition for intestinal pico sulphate-containing detergent according to the present invention comprises the steps of: adding a pico sodium sulfate to a binding solvent and dissolving a sticky polymer binder therein to prepare a binding solution; Attaching the binding solution to the surface of calcium carbonate and removing the binding solvent to prepare a primary granule; Mixing the primary granules with magnesium oxide to prepare a primary mixture; Mixing the primary mixture with citric acid to prepare a secondary mixture; And a control unit.
또한 본 발명에 따른 피코황산나트륨 함유 장 세척용 조성물은, 피코황산나트륨 10 mg, 산화나그네슘 3.5 g, 구연산 12 g, 탄산칼슘 300 ~ 800 mg, 슈크랄로스 25 mg, 오렌지 분말 40 mg, 히드록시프로필셀룰로오스 3 ~ 15 mg으로 구성된 것을 특징으로 한다.
The composition for intestinal pico sulphate-containing detergent according to the present invention may further contain 10 mg of pico sodium sulfate, 3.5 g of magnesium oxide, 12 g of citric acid, 300 to 800 mg of calcium carbonate, 25 mg of sucralose, 40 mg of orange powder, And 3 to 15 mg of cellulose.
본 발명에 따라 제조되는 장 세척용 조성물은, 피코황산나트륨을 비롯한 활성성분들이 골고루 분포되어 있어서 품질이 균일하고, 유연물질이 발생하지 않으며, 정제 제조가 용이하고, 물에 용해하였을 때 비린 맛이 거의 없어서 복약 순응도를 향상시킬 수 있는 효과가 있다.
The composition for intestinal cleansing according to the present invention is characterized in that active ingredients including sodium picosapenta sulfate are uniformly distributed so that the quality is uniform, no flexible substance is produced, the preparation of tablets is easy, and when the composition is dissolved in water, There is an effect that the compliance of medication can be improved.
도 1은 본 발명의 실시예에 따라 제조된 장 세척용 조성물을 정제수에 용해한 상태를 촬영한 사진,
도 2는 본 발명의 비교예에 따라 제조된 장 세척용 조성물을 정제수에 용해한 상태를 촬영한 사진이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph of a state in which a composition for intestinal washing according to an embodiment of the present invention is dissolved in purified water,
2 is a photograph of a state in which a composition for intestinal washing prepared according to a comparative example of the present invention is dissolved in purified water.
본 발명에 따른 장 세척용 조성물은 피코황산나트륨과 산화마그네슘 및 구연산을 활성성분으로 포함하며, 여기에 부형제와 감미제, 착향제 및 결합제를 포함하여서 구성된다. 그런데 상기 조성물 1회 복용량 중에 포함되어 있는 각 활성성분들의 함량은 피코황산나트륨이 10 mg, 산화마그네슘이 3.5 g, 구연산이 12 g 으로써, 피코황산나트륨의 함량이 상기 조성물 전체의 0.06중량% 정도에 불과하기 때문에 각 유효성분들이 골고루 분포된 균질의 조성물을 제조하는 것이 매우 곤란하다.The composition for intestinal washing according to the present invention comprises pico sodium sulfate, magnesium oxide and citric acid as an active ingredient, and comprises an excipient, a sweetener, a flavoring agent and a binder. However, the content of each active ingredient contained in the single dose of the composition is 10 mg of pico sodium sulfate, 3.5 g of magnesium oxide and 12 g of citric acid, and the content of sodium picosulfurate is only 0.06% by weight of the total composition Therefore, it is very difficult to prepare a homogeneous composition in which each of the active ingredients is uniformly distributed.
그래서 본 발명에서는 상기 조성물 중에 피코황산나트륨의 함량을 균일하게 분포시키기 위하여 먼저 탄산칼슘 입자의 표면에 피코황산나트륨을 부착하여 과립물을 제조하고, 상기 과립물에다 산화마그네슘과 구연산을 차례로 혼합하여서 장 세척용 조성물을 제조하는 것을 특징으로 한다.Therefore, in the present invention, in order to uniformly distribute the sodium picosapenta sulfate content in the composition, sodium picosulfate is first attached to the surface of the calcium carbonate particles to prepare granules. Magnesium oxide and citric acid are added to the granules in order, Wherein the composition is prepared.
참고로 만일 피코황산나트륨을 구연산과 혼합하여 과립화하면 활성성분이 분해되어 유연물질이 발생할 우려가 있고, 산화마그네슘과 혼합하여 과립화하면 혼합기나 유동층 조립기 등 제조 장비에 미세분말인 산화마그네슘이 들러붙는 현상이 발생하기 때문에 특히 피코황산나트륨의 손실을 방지할 수가 없다.
For example, if sodium bicarbonate is mixed with citric acid, the active ingredient is decomposed to form a flexible substance. When the granule is mixed with magnesium oxide, the fine powder of magnesium oxide adheres to the manufacturing equipment such as a mixer or a fluidized bed granulator It is impossible to prevent the loss of sodium p-sodium sulfate in particular.
이하, 본 발명에 따른 피코황산나트륨 함유 장 세척용 조성물의 제조방법을 구체적으로 설명하면 다음과 같다.Hereinafter, a method for preparing a composition for intestinal pico sulphate-containing detergent according to the present invention will be described in detail.
먼저 피코황산나트륨을 결합용매에 투입하고, 여기에 점착성 고분자 결합제를 용해하여 결합액을 제조한다. 이때, 상기 결합용매는 물과 에탄올이 1 : 4의 중량비로 혼합된 혼합용매로서, 피코황산나트륨 10 중량부에 대하여 상기 혼합용매70 ~ 80 중량부를 사용하는 것이 바람직하다.First, pico sodium sulfate is added to a binding solvent, and a sticking polymer binder is dissolved therein to prepare a binding solution. In this case, the coupling solvent is a mixed solvent in which water and ethanol are mixed at a weight ratio of 1: 4, and 70 to 80 parts by weight of the mixed solvent is preferably used relative to 10 parts by weight of sodium picosapenta sulfate.
상기 결합용매에서 물은 피코황산나트륨을 용해하는 기능을 하고, 에탄올은 점도를 조절하는 기능을 하는데, 에탄올에 비해 물의 사용량이 적은 이유는 다음 공정에서 탄산칼슘에 잔류하는 수분의 양을 최소화하기 위한 것이다. 만일 탄산칼슘 중에 수분이 남게 되면, 다른 활성성분인 구연산이나 산화마그네슘과 반응하여 유연물질이나 가스가 발생할 수 있고, 나아가 제제의 안정성을 저하시키는 문제가 발생한다.In the coupling solvent, water functions to dissolve sodium picosulfate and ethanol functions to control viscosity. The reason why the amount of water used is smaller than that of ethanol is to minimize the amount of water remaining in the calcium carbonate in the next step . If water remains in the calcium carbonate, it may react with other active ingredients, such as citric acid or magnesium oxide, to generate a soft substance or gas, which further lowers the stability of the preparation.
그리고 상기 점착성 고분자 결합제로는 포비돈, 메틸셀룰로오스, 히드록시메틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 히드록시에틸셀룰로오스, 젤라틴, 구아 검, 크산탄 검 중에서 선택된 어느 하나 이상을 사용한다.As the adhesive polymer binder, at least one selected from povidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum and xanthan gum is used.
상기 점착성 고분자 결합제의 사용량은 상기 피코황산나트륨 10 중량부에 대하여 3 내지 15 중량부를 사용한다. 이때, 상기 점착성 고분자 결합제의 사용량이 3 중량부 미만이면 다음 공정에서 피코황산나트륨이 탄산칼슘의 표면에 잘 부착되지 않는 문제가 있고, 반대로 15 중량부를 초과하면 점도가 너무 높아져서 결합액으로 사용할 수가 없게 된다. The amount of the adhesive polymer binder to be used is 3 to 15 parts by weight based on 10 parts by weight of the sodium picosulfate. If the amount of the adhesive polymer binder is less than 3 parts by weight, sodium pico sodium sulfate may not be adhered to the surface of the calcium carbonate in the next step. On the other hand, if the amount exceeds 15 parts by weight, viscosity becomes too high, .
그리고 결합액의 점도가 높아지면, 다시 결합용매의 사용량을 늘려야 하는데, 만일 탄산칼슘에 과도한 양의 결합용매를 투입하게 되면 슬러리와 같은 현상이 발생하여 이를 건조하는데 많은 시간이 소요될 뿐 아니라, 또한 건조 후 산제에 적합한 입자를 만들기 위해 수차례의 분쇄 공정을 거쳐야 하기 때문에 작업성이 매우 떨어지는 단점이 있다.
If the viscosity of the coupling solution is increased, the amount of the coupling solvent must be increased again. If an excessive amount of coupling solvent is added to the calcium carbonate, a phenomenon similar to that of the slurry occurs and it takes much time to dry the coupling solvent. It is disadvantageous in that the workability is very low because it is required to undergo several grinding steps to make particles suitable for the post-baking agent.
다음은 상기 결합액을 탄산칼슘의 표면에 부착하고, 상기 결합용매를 제거하여 1차 과립물을 제조한다. 즉, 통상적인 하이 쉐어 믹서(High Share mixer)에다 탄산칼슘을 투입하고 여기에 결합액을 서서히 투입하면서 상기 탄산칼슘의 표면에 피코황산나트륨을 부착시킨 다음, 통상의 열풍건조기를 이용하여 결합용매를 제거한다. 이렇게 하면, 상기 결합액 속에 포함되어 있던 피코황산나트륨이 상기 점착성 고분자 결합제에 의해서 탄산칼슘의 표면에 부착된다.Next, the binding solution is attached to the surface of calcium carbonate, and the binding solvent is removed to prepare a primary granule. That is, calcium carbonate is added to a conventional high-share mixer, and the bonding liquid is slowly added thereto, and sodium picosapenta sulfate is attached to the surface of the calcium carbonate, and then the bonding solvent is removed using a conventional hot air drier do. In this way, sodium picosulfate contained in the binding liquid is attached to the surface of the calcium carbonate by the adhesive polymer binder.
이때 작업시간을 단축하기 위해서는 유동층 조립기 내에 결합액을 분사하여 탄산칼슘에 피코황산나트륨을 부착함과 동시에 결합용매를 건조시킬 수도 있으나, 이렇게 하면 작업공정에 상당량의 손실이 발생하기 때문에 이를 고려하여 각 유효성분들의 사용량을 증량하여야 하는 문제가 있다.
In this case, in order to shorten the working time, it is possible to spray the bonding liquid into the fluidized bed granulator to attach the sodium picosulfate to the calcium carbonate and dry the binding solvent. However, since this results in a considerable loss in the working process, There is a problem that the usage amount of the users must be increased.
상기 탄산칼슘의 사용량은 상기 피코황산나트륨 10 중량부에 대하여 300 내지 800 중량부 인 것이 바람직하다. 이때, 상기 탄산칼슘의 함량이 300 중량부 미만이면 본 발명에 따른 장 세척용 조성물을 복용하기 위하여 물에 용해했을 때 신맛이 너무 강해져서 복약하기에 불편한 문제가 있고, 반대로 800 중량부를 초과하면 용액의 투명도가 현저하게 떨어지고 일부 잔류물이 남아 있어서 제품으로 사용하기에는 부적합한 문제가 있다.
The amount of the calcium carbonate is preferably 300 to 800 parts by weight based on 10 parts by weight of the sodium picosulfate. If the content of calcium carbonate is less than 300 parts by weight, there is a problem that when the composition is used in water for taking the composition for intestinal washing according to the present invention, the sour taste becomes too strong and it is inconvenient for taking medicines. On the other hand, The transparency of the product is remarkably lowered and some residues remain, which makes it unsuitable for use as a product.
다음으로 상기 1차 과립물, 즉 피코황산나트륨이 코팅된 탄산칼슘을 40 메시(mesh)의 체망으로 정립 한 다음, 여기에 산화마그네슘에 혼합하여 1차 혼합물을 제조한다. 이때, 상기 산화마그네슘의 사용량은 유효 사용량의 비율에 따라 피코황산나트륨 10 중량부에 대하여 3,500 중량부를 사용한다.Next, the primary granule, that is, calcium carbonate coated with sodium picosulfate is sieved with a mesh of 40 mesh, and then mixed with magnesium oxide to prepare a primary mixture. At this time, the amount of magnesium oxide used is 3,500 parts by weight based on 10 parts by weight of sodium picosulfate, depending on the effective amount.
이어 상기 1차 혼합물에다 마지막 활성성분인 구연산 12,000 중량부를 혼합하여 2차 혼합물을 제조한다. 이때, 각 구성성분들을 균일하게 혼합하기 위하여 상기 구연산은 3회에 나누어 골고루 혼합하는 것이 바람직하다. 그리고, 필요에 따라 감미제인 수크랄로오스와 착향제인 오렌지 분말을 적당량 혼합한다.
Then, the first mixture is mixed with 12,000 parts by weight of citric acid, which is the last active ingredient, to prepare a second mixture. At this time, in order to uniformly mix the components, it is preferable to mix the citric acid three times and mix evenly. If necessary, sucralose, a sweetening agent, and orange powder as a flavoring agent are mixed in an appropriate amount.
본 발명에 따라 제조되는 피코황산나트륨 함유 장 세척용 조성물은 산제나 과립제 또는 정제 형태로 제제화 할 수 있으며, 복용시에는 1회 복용량을 150 ~ 180 ml 정도의 식용수에 용해하여 복용한다.
The composition for intestinal washing containing sodium picosaproate prepared according to the present invention can be formulated in the form of an acid or granule or a tablet, and when taken, a dose of about 150 to 180 ml is dissolved in the drinking water to be taken.
이하, 본 발명에 대한 실시예를 설명한다. 하기 실시예에서 각 구성성분들의 사용량은 편의상 1회 복용량을 기준으로 기재한다.
Hereinafter, embodiments of the present invention will be described. In the following examples, the amount of each component to be used is described on the basis of a single dose for convenience.
실시예Example 1 One
물 15 mg과 에탄올 60 mg으로 이루어진 혼합용매에다, 피코황산나트륨 10 mg을 투입하고, 여기에 히드록시프로필셀룰로오스(HPC) 5 mg을 용해하여 결합액을 제조하였다.10 mg of sodium picosulfate was added to a mixed solvent composed of 15 mg of water and 60 mg of ethanol, and 5 mg of hydroxypropylcellulose (HPC) was dissolved therein to prepare a binding solution.
하이 쉐어 믹서(High Share mixer) 내에 탄산칼슘 500 mg을 혼합시키고, 여기에 상기 결합액을 서서히 투입한 다음, 열풍건조기에서 45℃의 온도로 4시간 동안 건조시켜서 1차 과립물을 제조하였다. 500 mg of calcium carbonate was mixed in a high share mixer, the binding solution was gradually added thereto, and the mixture was dried in a hot air drier at a temperature of 45 캜 for 4 hours to prepare a first granule.
상기 1차 과립물을 40 mesh의 체망으로 정립 한 다음, 여기에 산화마그네슘 3.5 g을 혼합하고, 이어서 구연산 12 g을 각각 4 g 씩 나누어 3회에 걸쳐서 투입하고, 추가로 슈크랄로오스 25 mg과 오렌지 분말 40 mg을 혼합하여 본 발명에 따른 장 세척용 조성물을 제조하였다.The above primary granules were sieved with a 40 mesh mesh, mixed with magnesium sulfate (3.5 g), and then 12 g of citric acid (4 g) were added to the granules three times. Further, 25 mg of sucralose And 40 mg of orange powder were mixed to prepare a composition for intestinal washing according to the present invention.
상기 장 세척용 조성물을 정제수 170mL에 용해하고 관능시험을 실시한 결과, 비린 맛은 전혀 없고, 오렌지 향과 함께 약간 달고 신맛이 있어서 복용하기에 아무런 거부감이 없었으며, 첨부 도 1의 사진에서 보는 바와 같이, 투명도가 매우 높은 것을 확인할 수 있었다.
The composition for intestinal washing was dissolved in 170 mL of purified water and subjected to a sensory test. As a result, there was no irritating taste, no irritation due to the slightly sweet and sour taste with orange flavor, , And transparency was very high.
실시예Example 2 내지 4 2 to 4
상기 실시예 1과 동일한 방법으로 실시하되, 결합제의 종류와 함량을 다음 표 1과 같이 변경하여 실시예 2 내지 4의 장세척용 조성물을 제조하였다. 다음 표 1 에서, 'HPC'는 ‘히드록시프로필셀룰로오스’의 약자이고, 'HPMC'는 ‘히드록시프로필메틸셀룰로오스’의 약자이며, ‘PVP'는 ‘폴리비닐피롤리돈’의 약자이다.
The same procedures as in Example 1 were carried out except that the types and contents of the binders were changed as shown in Table 1 to prepare the intestinal washing compositions of Examples 2 to 4. In the following Table 1, 'HPC' is an abbreviation of 'hydroxypropylcellulose', 'HPMC' is an abbreviation of 'hydroxypropylmethylcellulose', and 'PVP' is an abbreviation of 'polyvinylpyrrolidone'.
성분activation
ingredient
결합제
Binder
상기 실시예 2 내지 4에 따라 제조된 장 세척용 조성물을 각각 정제수 170mL에 용해하고 관능시험을 실시한 결과, 모두 상기 실시예 1의 장 세척용 조성물에 비해 투명도는 다소 떨어졌으나, 맛은 실시예 1과 비슷하여 복용하기에 아무런 거부감이 없는 것으로 나타났다.
The compositions for intestinal washing prepared according to Examples 2 to 4 were each dissolved in 170 ml of purified water and subjected to a sensory test. As a result, the transparency was slightly lower than that of Example 1, And it seems that there is no disinclination to take it.
비교예Comparative Example 1 내지 4 1 to 4
상기 실시예 1과 동일한 방법으로 실시하되, 탄산칼슘의 함량을 다음 표 1과 같이 변경하여 비교예 1 내지 4의 장세척용 조성물을 제조하였다.
The contents of calcium carbonate were changed as shown in Table 1 below in the same manner as in Example 1 to prepare the long-term cleaning compositions of Comparative Examples 1 to 4.
성분activation
ingredient
상기 비교예 1 내지 4에 따라 제조된 장 세척용 조성물을 각각 정제수 170mL에 용해하고 관능시험을 실시한 결과, 탄산칼슘의 함량이 기준량 보다 적은 비교예 1 및 2의 경우, 용액의 투명도나 용해도는 비교적 양호 하였으나, 신맛이 너무 강해서 복약하기에 상당한 거부감이 있는 것을 나타났다.The composition for intestinal washing prepared according to Comparative Examples 1 to 4 was dissolved in 170 mL of purified water and subjected to a sensory test. As a result, in Comparative Examples 1 and 2 in which the content of calcium carbonate was smaller than the reference amount, the transparency and solubility of the solution were relatively low But the sour taste was so strong that there was a considerable dislike to take the medication.
반면, 탄산칼슘의 함량이 기준량 보다 적은 비교예 3 및 4의 경우, 용액의 투명도가 현저하게 떨어지며, 텁텁한 맛이 강하게 느껴지며, 특히 비교예 4의 경우에는 일부 용해되지 않는 잔류물이 남아 있어서 제품으로 사용하기에는 부적합한 것으로 나타났다. 첨부 도 2의 사진은 상기 비교예 3의 결과를 촬영한 사진이다.On the other hand, in the case of Comparative Examples 3 and 4 in which the content of calcium carbonate is smaller than the reference amount, the transparency of the solution remarkably decreased and the strong taste became strong. Particularly in the case of Comparative Example 4, And it is not suitable for use as 2 is a photograph of the result of Comparative Example 3. FIG.
Claims (6)
상기 결합액을 탄산칼슘 입자의 표면에 부착하고, 상기 결합용매를 제거하여 1차 과립물을 제조하는 단계와;
상기 1차 과립물에다 산화마그네슘을 혼합하여 1차 혼합물을 제조하는 단계와;
상기 1차 혼합물에다 구연산을 혼합하여 2차 혼합물을 제조하는 단계;
를 포함하는 것을 특징으로 하는 피코황산나트륨 함유 장 세척용 조성물의 제조방법.
Adding pico sodium sulfate to a binding solvent and dissolving the adhesive polymer binder to prepare a binding solution;
Attaching the binding liquid to the surface of the calcium carbonate particles and removing the binding solvent to prepare a primary granule;
Mixing the primary granules with magnesium oxide to prepare a primary mixture;
Mixing the primary mixture with citric acid to prepare a secondary mixture;
Wherein the composition comprises sodium hypochlorite and sodium hypochlorite.
The method according to claim 1, wherein the coupling solvent is a mixed solvent in which water and ethanol are mixed at a weight ratio of 1: 4, and the amount thereof is 70 to 80 parts by weight per 10 parts by weight of sodium picosulfate. ≪ / RTI >
The adhesive polymeric binder according to claim 1 or 2, wherein the adhesive polymer binder is selected from the group consisting of povidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, Wherein the composition is at least one selected from the group consisting of sodium hypochlorite and sodium hypochlorite.
[6] The method of claim 3, wherein the adhesive polymer binder is used in an amount of 3 to 15 parts by weight based on 10 parts by weight of the sodium picosulfate.
The method of claim 1 or 2, wherein the calcium carbonate is used in an amount of 300 to 800 parts by weight based on 10 parts by weight of the picosapenta sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130092376A KR101517520B1 (en) | 2013-08-05 | 2013-08-05 | A process for preparing bowel cleansing composition containing pico sodium sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130092376A KR101517520B1 (en) | 2013-08-05 | 2013-08-05 | A process for preparing bowel cleansing composition containing pico sodium sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150016666A true KR20150016666A (en) | 2015-02-13 |
| KR101517520B1 KR101517520B1 (en) | 2015-05-04 |
Family
ID=52573314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130092376A Active KR101517520B1 (en) | 2013-08-05 | 2013-08-05 | A process for preparing bowel cleansing composition containing pico sodium sulfate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101517520B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017031121A1 (en) * | 2015-08-17 | 2017-02-23 | Liang Alfred Chi-Yeh | Liquid formulations containing picosulfate and magnesium citrate |
| EP3120835A4 (en) * | 2014-03-19 | 2017-10-18 | Pharmbio Korea Co. Ltd. | Liquid pharmaceutical composition |
| WO2021133017A1 (en) * | 2019-12-23 | 2021-07-01 | 주식회사 비보존 | Colonic purgative composition |
| US12458634B2 (en) | 2016-07-08 | 2025-11-04 | Ferring B.V. | Stabilized liquid formations containing picosulfate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2702152A1 (en) | 2007-10-12 | 2009-04-16 | Haijun Xu | Process for the manufacture of a pharmaceutical product |
| KR101155099B1 (en) | 2012-03-29 | 2012-06-11 | 남봉길 | Method for preparing intestinal lavage composition and composition for intestinal lavage produced thereby |
-
2013
- 2013-08-05 KR KR1020130092376A patent/KR101517520B1/en active Active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3120835A4 (en) * | 2014-03-19 | 2017-10-18 | Pharmbio Korea Co. Ltd. | Liquid pharmaceutical composition |
| US9827231B2 (en) | 2014-03-19 | 2017-11-28 | Ferring International Center S.A. | Liquid pharmaceutical composition |
| US10624879B2 (en) | 2014-03-19 | 2020-04-21 | Ferring International Center S.A. | Liquid pharmaceutical composition |
| US11191753B2 (en) | 2014-03-19 | 2021-12-07 | Ferring International Center Sa. | Liquid pharmaceutical composition |
| WO2017031121A1 (en) * | 2015-08-17 | 2017-02-23 | Liang Alfred Chi-Yeh | Liquid formulations containing picosulfate and magnesium citrate |
| CN109310774A (en) * | 2015-08-17 | 2019-02-05 | 费林股份公司 | Liquid preparation containing picosulfate and magnesium citrate |
| US11612592B2 (en) | 2015-08-17 | 2023-03-28 | Ferring B.V. | Liquid formulations containing picosulfate and magnesium citrate |
| US12458634B2 (en) | 2016-07-08 | 2025-11-04 | Ferring B.V. | Stabilized liquid formations containing picosulfate |
| WO2021133017A1 (en) * | 2019-12-23 | 2021-07-01 | 주식회사 비보존 | Colonic purgative composition |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101517520B1 (en) | 2015-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60319252T2 (en) | FORMULATION OF ACETAMINOPHES AND TRAMADOL WITH DELAYED RELEASE | |
| JP5775223B2 (en) | Granules for intraoral rapidly disintegrating tablets | |
| DE69530759T2 (en) | FILM COATED TABLET CONTAINING PARACETAMOL AND DOMPERIDONE | |
| KR101077061B1 (en) | Solid drug for oral use | |
| HU230771B1 (en) | Sustained release vitamin composition | |
| KR101517520B1 (en) | A process for preparing bowel cleansing composition containing pico sodium sulfate | |
| DE69111574T2 (en) | Medicinal product containing polycarbophil calcium. | |
| CN107737128A (en) | A kind of Favipiravir tablet composition | |
| JPH0717866A (en) | Medicinal composition | |
| KR20040086364A (en) | Improvements in or relating to compositions | |
| CN104586805A (en) | Quetiapine fumarate sustained-release tablet and preparation method thereof | |
| JP2013010753A (en) | Sugar-coated preparation and production method for the same | |
| JPWO2019202968A1 (en) | Easy-to-take granules and their manufacturing method | |
| JPS5944311A (en) | Slow-releasing granule and its preparation | |
| TWI286072B (en) | Sleeping medicine formed by coating solid | |
| CN104739835A (en) | Novel pharmaceutical composition for treating diabetes | |
| CN105407875A (en) | Stable pharmaceutical composition in form of coated tablet comprising granules of isoniazid and granules of rifapentine against tuberculosis and process for preparing same | |
| CN101198319A (en) | Granular preparations containing biguanide compounds | |
| KR20180091572A (en) | Colonic purgative composition for oral administration | |
| EP0319074A1 (en) | Pharmaceutical composition and process for its preparation | |
| JP2022072050A (en) | Orally disintegrating tablet containing edoxaban | |
| KR20070091041A (en) | Oral Disintegration Solid Forms Containing Povidone Iodine | |
| JP2007238451A (en) | Pharmaceutical composition and method for producing the same | |
| JPH09208468A (en) | Tablets containing p-chloro-N- (2-morpholinoethyl) benzamide | |
| JPH1045580A (en) | Method for producing carnitine chloride-containing preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20130805 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140728 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20150120 Patent event code: PE09021S02D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150417 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20150428 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20150429 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20180424 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180424 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190425 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190425 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200428 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210426 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220426 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230427 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240424 Start annual number: 10 End annual number: 10 |